Showing results (261-270 of 322) with videos related to

Sort By:
Pageof 33
Pharmaceutics|July 29, 2023
What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 VaccineUrska Kamensek, Maja Cemazar, Simona Kranjc Brezar, et al.
BMJ Open|August 3, 2021
Trainee perspective of the causes of stress and burnout in surgical training: a qualitative study from WalesDavid Bryan Thomas Robinson, Oliver Luton, Katie Mellor, et al.
AIDS Research and Human Retroviruses|November 14, 1998
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3D P Francis, T Gregory, M J McElrath, et al.
Vaccine|September 24, 2013
Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of ageGeoffrey J Gorse, Ann R Falsey, Carol M Johnson, et al.
Journal of Cheminformatics|June 18, 2015
A practical Java tool for small-molecule compound appraisalParisa Amani, Todd Sneyd, Sarah Preston, et al.
Annals of Internal Medicine|August 15, 1996
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation GroupB S Graham, M C Keefer, M J McElrath, et al.
NPJ Digital Medicine|March 16, 2024
Indigenous data governance approaches applied in research using routinely collected health data: a scoping reviewTeyl Engstrom, Elton H Lobo, Kristie Watego, et al.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
Vaccine|March 10, 1998
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M J McElrath, T J Matthews, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
Pageof 33